Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Nocturia

Nocturia

Nocturia is a condition characterized by the need to wake up one or more times during the night to urinate.
It can have various underlying causes, such as overactive bladder, prostate issues, or hormonal imbalances.
Proper management of nocturia is important to ensure restful sleep and overall well-being.
PubCompare.ai can assist researchers in optimizing nocturia studies by helping them identify the best research protocols from literature, preprints, and patents.
Its AI-driven comparisons can enhance reproducibility and accuracy, taking your nocturia research to new heights and advancing our understanding of this common yet complex condition.

Most cited protocols related to «Nocturia»

1
Validation of the Heart Failure Symptom Perception Scale
Physical HF symptoms were measured using the HFSPS, V.3, an 18-item Likert scale. The original scale22 (link) was expanded from 12 items to 18 to capture the more subtle symptoms of HF. Importantly, the development of the original HFSPS and this current 18 item version were guided by Lenz’s Theory of Unpleasant Symptoms, with respect to interactions among multiple symptoms, multiple influential pathophysiological mechanisms, situational factors, and performance (e.g. HRQOL and clinical event-risk).23 (link),24 (link) Additional items were added to assess dyspnea on exertion, fatigue, nocturia, and symptoms associated with right-sided congestion (i.e. abdominal swelling and loss of appetite).25 (link) The HFSPS asks participants how much they are bothered by symptoms in the past week using 5 response options ranging from 0 (I did not have the symptom) to 5 (extremely bothersome). Scores are summed with higher values indicating higher symptom burden.
Convergent validity provides evidence of validity by examining the correlation between different measures of a construct. To support convergent validity, correlation of theoretically-related construct measures should be high.26 ,27 (link) The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item Likert scale health status measure that assesses physical function, symptoms, social function, self-efficacy, and quality of life among patients with HF.28 (link) The KCCQ is a reliable and valid measure of health status responsive to change clinical status. The 6-item Physical Limitation subscale of the (KCCQ) was used to examine convergent validity. Scores range 1 to 36 on the Physical Limitation subscale. Higher scores indicate better function. The reliability of the Physical Limitation subscale is acceptable with a Cronbach’s alpha of 0.90. We hypothesized that the correlation between the HFSPS and KCCQ Physical Limitation subscale would be significant.
Discriminant validity examines differentiation of constructs that are theoretically different. To support discriminant validity, correlation between two different constructs should be low.26 ,27 (link) The Self-Care of HF Index (SCHFI) was used to quantify self-care.29 (link) The SCHFI v.6.2 is a 22-item scale using a 4-point self-report response format to measure self-care maintenance (adherence behaviors), self-care management (response to symptoms) and self-care confidence. The 6-item Self-Care Management score was used to examine discriminant validity for this analysis because it reflects how quickly participants recognized and responded symptoms as opposed to the physical experience of symptoms. Symptom recognition options ranged from 0 (I did not recognize it as a symptom of HF) to 4 (very quickly). Response to symptoms options included rating the likelihood of taking action to manage symptoms (e.g. taking an extra diuretic, reducing fluid intake) from 1 (not likely) to 4 (very likely). Scores are standardized to range from 0 to 100 with higher values indicated better symptom response behaviors. The Self-Care Management subscale of the SCHFI is multidimensional with a two factor structure representing symptom evaluation and treatment implementation. Therefore, a global reliability index is used to assess internal consistency. The global reliability index derived from the weighted least squares means and variance is 0.77 and 0.76 respectively.30 (link) We hypothesized that the correlation between the HFSPS and SCHFI Self-Care Management subscale would be weak and insignificant.
We completed a review of the electronic medical record at 1 year looking specifically for HF-related emergency room visits, hospitalizations or mortality. For the vast majority of events data were extracted directly from discharge summaries all participants received care locally and were part of an extensively-linked electronic medical record system. We also contacted study participants by phone to inquire about events that occurred outside of the health system network; we solicited sufficient detail directly from participants or their family members to determine whether or not the event was primarily related to their HF or for other reasons. All events underwent adjudication by two separate evaluators until 100% agreement was reached about the underlying reasons for emergent healthcare utilization.
Jurgens C.Y., Lee C.S, & Riegel B. (2017). Psychometric analysis of the Heart Failure Somatic Perception Scale as a measure of patient symptom perception. The Journal of cardiovascular nursing, 32(2), 140-147.
Publication 2015
Abdomen Anorexia Cardiomyopathies Debility Diuretics Dyspnea factor A Family Member Fatigue Hospitalization Nocturia Patient Discharge Patients Physical Examination Self-Management Self Confidence Symptom Evaluation
2
Overactive Bladder Symptom Score Evaluation
The original Japanese version of the OABSS consists of a total of 4 questions regarding daytime frequency, nocturia, urgency, and urgency incontinence (Appendix 1). Through the weighing of each symptom by use of the influence rate from the epidemiologic database on lower urinary tract symptoms (LUTS), which included 4,570 Japanese residents older than 40 years of age, the relative weight of the maximal score was designated to be 2:3:5:5 for daytime frequency, nocturia, urgency, and urgency incontinence, respectively [6 (link)]. The overall score is the sum of the 4 scores, and the diagnostic criteria for OAB are a total OABSS of 3 or more with an urgency score for Question 3 of 2 or more [12 (link)]. In the event that the OABSS is used as the standard for the assessment of the severity of OAB, it is recommended that a total score of 5 or less be defined as mild, a score of 6 to 11 as moderate, and a score of 12 or more as severe [13 ]. In this study, the original Japanese version of the OABSS was translated into Korean, but the English version [6 (link)] was used as a reference.
Jeong S.J., Homma Y, & Oh S.J. (2011). Korean Version of the Overactive Bladder Symptom Score Questionnaire: Translation and Linguistic Validation. International Neurourology Journal, 15(3), 135-142.
Publication 2011
Diagnosis Japanese Koreans Lower Urinary Tract Symptoms Nocturia
3
Retrospective Analysis of Interstitial Cystitis
This study retrospectively analyzed the data for a large cohort of patients with IC/BPS. The study included patients who attended our hospital between October, 1997 and March, 2019 with clinical symptoms of urinary frequency, urgency, and nocturia, with or without bladder pain. Patients had been treated with lifestyle modification and medication for the bladder symptoms such as antimuscarinics, beta-3 adrenoceptor agonists, and non-steroid anti-inflammatory agents (NSAID) but the bladder symptoms remained. Patients with chronic urinary retention, acute or chronic urinary tract infection, urodynamic stress incontinence, pelvic organ prolapse, possible neurogenic voiding dysfunction, previous genital tract or lower urinary tract surgery, previous irradiation, or a previous history of genitourinary tract malignancy were excluded from the analysis. All the patients underwent a videourodynamic study (VUDS) and cystoscopic HD examination. Based on the VUDS results, patients with intrinsic sphincter deficiency, neurogenic bladder, or overt bladder outlet obstruction were excluded from the analysis.
Finally, 486 patients were diagnosed to have IC/BPS and included in this study (65 men, 421 women). Data for their baseline clinical symptoms, disease duration, medical co-morbidity, urodynamic findings, and cystoscopic characteristics (MBC, glomerulations, and Hunner’s lesion) were extracted from the medical records. This included scores for the ICSI, Interstitial Cystitis Problem Index (ICPI), and O’Leary–Sant Symptom index (OSS)25 (link).
The study was approved by the Research Ethics Committee of the Hualien Tzu Chi Hospital (IRB: 105-25-B). Because of the retrospective nature of the study, the requirement for informed consent was waived. All methods used in this study were carried out in accordance with relevant guidelines and regulations.
Yu W.R., Jhang J.F., Ho H.C., Jiang Y.H., Lee C.L., Hsu Y.H, & Kuo H.C. (2021). Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment. Scientific Reports, 11, 455.
Full text: Click here
Publication 2021
Adrenergic beta-Agonists Anti-Inflammatory Agents, Non-Steroidal Bladder Neck Obstruction Cystoscopy Ethics Committees, Clinical Genitalia Genitourinary Cancer Interstitial Cystitis Malignant Neoplasms Muscarinic Antagonists Neurogenesis Neurogenic Urinary Bladder Nocturia Pain Patients Pelvic Organ Prolapse Pharmaceutical Preparations Radiotherapy Sperm Injections, Intracytoplasmic Urinary Bladder Urinary Stress Incontinence Urinary Tract Urinary Tract Infection Urine Urodynamics Urologic Surgical Procedures Woman
4
Sacral Neuromodulation Procedure Outcomes

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Diagnosis Ethnicity Gender Interstitial Cystitis Medical Devices Neurogenesis Neurogenic Urinary Bladder Nocturia Operative Surgical Procedures Overactive Bladder Patients Retention (Psychology) Sacrum Urinary Bladder Urinary Stress Incontinence
5
Developing and Validating the LURN-Symptom Index
On October 23, 2017, the LURN Steering Committee convened a panel of experts from its membership. The expert review panel was comprised of 24 participating investigators in the LURN Network. These experts included 10 urologists, 5 urogynecologists, 4 patient reported outcome measurement specialists, 3 quantitative specialists, a nephrologist, and a transplant surgeon. Of the 24 participants, 10 were women. Only the LUTS clinicians on the panel (7 women; 8 men) participated in the discussion and decision-making regarding the composition of the brief clinical form.
We employed a modified Delphi approach to facilitating group discussion and consensus-based decision-making. This four-hour meeting had two objectives: 1) To develop an outcome tool with subscales derived from the CASUS questionnaire; and 2) To develop a brief clinical form that improves upon existing measures of clinical symptom reporting, derived from the set of questions selected under the first objective. The first objective included reviewing results of factor analyses and making final decisions on the naming and item content of subscales (Incontinence, Urgency, Voiding Difficulty, Bladder Pain, Nocturia), and selecting additional clinically-relevant questions, resulting in the LURN SI-29 as reported elsewhere.9 The second objective – the brief clinical form – is the subject of this manuscript.
As reported elsewhere, the first half of this meeting, with discussion and input from the entire panel of LURN investigators, resulted in the formation of the LURN SI-29, comprised of five multi-item subscales and nine additional questions not included in any of those subscales. Optional item sets were proffered, discussed, and decided upon through a consensus-building discussion. The resulting composition was unanimously endorsed. Upon completion of this 29-item set, the clinicians on the panel continued discussion in the second half of the meeting, with the instruction of selecting one to two items from each subscale and a finite number of items from among the miscellaneous nine items not included in one of the multi-item subscales. Discussion ensued, scale-by-scale, until consensus was reached on which item (or items) from each set should be included on the clinical form. The focus of discussion was on selecting those items that were regarded as actionable or at least indicative of the need for further clinical interrogation. All item selection decisions were made without member dissent and were thereby assumed to be unanimous.
The 10 items (including frequency, nocturia, urgency, incontinence, bladder pain, voiding, and post-micturition symptoms) were summed to form a 10-item LURN-Symptom Index (LURN SI-10), with score range from 0 to 38. We used all available response data from the 12-month assessment to evaluate the validity of the brief clinical form. Specifically, we compared the LURN SI-10 total score to participant responses on the general screening questions regarding bladder and urinary function described above. Medians and interquartile ranges (IQR) for LURN SI-10 scores were reported by response level on the general screening questions, and relationships between LURN SI-10 scores and responses to the screening questions were examined using proportional odds models. The LURN SI-10 score was then compared to the AUA-SI and the UDI-6 using Pearson correlations and ROC curves. ROC curves were plotted to illustrate the diagnostic ability of various LURN-SI discrimination thresholds as binary classifiers of case definitions defined by the AUA-SI, UDI-6, and the four global screening items from CASUS.
Cella D., Smith A.R., Griffith J.W., Kirkali Z., Flynn K.E., Bradley C.S., Jelovsek J.E., Gillespie B.W., Helfand B.T., Talaty P, & Weinfurt K.P. (2019). A New Brief Clinical Assessment of Lower Urinary Symptoms for Women and Men: The LURN Symptom Index – 10 (LURN SI-10). The Journal of urology, 203(1), 164-170.
Publication 2019
Diagnosis Discrimination, Psychology Grafts Lutein Nephrologists Nocturia Pain Specialists Surgeons Urinary Bladder Urination Urine Urologists Woman

Most recents protocols related to «Nocturia»

1
Urodynamics Assessment of SUI in Iranian Women
All participants were recruited by convenience sampling method. SUI patients were diagnosed using a urodynamic test by urogynecologists at the Urogynecology Outpatient Clinic of Imam Khomeini and Hashemi Nezhad hospitals located in Tehran. If mixed symptoms were present, such as frequency, urgency or nocturia, patients with predominately SUI as a chief complaint were included in the study. Healthy individuals without any form of urinary incontinence using the International Consultation on Incontinence Questionnaire-short form (ICIQ-UI SF) with a score of zero, were recruited from staffs of the same two hospitals where patients were selected. All eligible women aged between 20–55 years, prior to menopause were included in the study. The exclusion criteria for all participants were as follow: body mass index (BMI) > 30 kg/m2, cesarean labor, pregnant or had delivered in the previous 6 months, diabetes, nervous system problems, urogenital prolapse above grade 2, hysterectomy, pelvic floor surgery in the previous 6 months, taking medications related to UI, breathing disorders such as asthma and chronic obstructive pulmonary disease (COPD), being infected with coronavirus infection which had led to lung damage, smoking, and being a professional athlete [13 ].
Before the study, all the participants received verbal information about the methods and aims of the study. They filled out the informed consent forms, and were assured that their data would be confidential and that they could leave the study at any time. Ultrasonic evaluations were performed in a center at the School of Rehabilitation Sciences of Iran University of Medical Sciences (IUMS).
Tavahomi M., Dadgoo M., Vasaghi-Gharamaleki B., Talebian S., Emami M, & Shanbehzadeh S. (2023). Lateral abdominal muscle thickness during breathing maneuvers in women with and without stress urinary incontinence. International Urogynecology Journal.
Publication 2023
Asthma Chronic Obstructive Airway Disease Coronavirus Infections Diabetes Mellitus Hysterectomy Imam Index, Body Mass Inpatient Lung Menopause Nocturia Obstetric Labor Operative Surgical Procedures Patients Pelvic Diaphragm Pelvic Organ Prolapse Pharmaceutical Preparations Professional Athletes Rehabilitation Systems, Nervous Ultrasonics Urinary Incontinence Urodynamics Woman
2
Phenotyping Sleep Disorders and Comorbidities
This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital, Taiwan (Certificate number: 201802210B0). The participants were recruited from the sleep center and health examination center of Kaohsiung Chang Gung Memorial Hospital from July 2018 through June 2022. The informed consent was obtained from each subject participating in the study. The adults (aged 20–70 years) who were diagnosed as subject with PS (defined as apnea–hypopnea index (AHI) < 5) or OSA (defined as AHI ≥ 5) after the full night polysomnographic studies in our sleep laboratory were included. The exclusion criteria were ongoing infections, autoimmune disease, use of immunosuppressive agent in the past 6 months, narcolepsy, severe obesity (body mass index [BMI] ≥ 35 kg/m2), and those with a BMI < 21 kg/m2. The patients with OSA and PS were further divided into two subgroups according to EDS (Epworth sleepiness scale (ESS) of more than 10), cognitive dysfunction (Mail-In Cognitive Function Screening Instrument (MCFSI) scale of more than 4), depression (defined as at least 1 of the 2 core symptoms of low mood and loss of interest, or taking antidepressant medication at Psychiatric Clinic), or the presence of subjective daytime fatigue, subjective memory impairment, morning headache, or nocturia (> 2 events/night).
Chen Y.C., Lin I.C., Su M.C., Hsu P.Y., Hsiao C.C., Hsu T.Y., Liou C.W., Chen Y.M., Chin C.H., Wang T.Y., Chang J.C., Lin Y.Y., Lee C.P, & Lin M.C. (2023). Autophagy impairment in patients with obstructive sleep apnea modulates intermittent hypoxia-induced oxidative stress and cell apoptosis via hypermethylation of the ATG5 gene promoter region. European Journal of Medical Research, 28, 82.
Full text: Click here
Publication 2023
Adult Antidepressive Agents Apnea Autoimmune Diseases Cognition Disorders, Cognitive Ethics Committees, Research Fatigue Headache Immunosuppressive Agents Index, Body Mass Infection Memory Deficits Mood Narcolepsy Nocturia Obesity, Morbid Patients Polysomnography Sleep Somnolence
3
Idiopathic Overactive Bladder Study
Forty-nine women, aged >18 years, with idiopathic OAB were included in this study. Additional inclusion criteria were OAB combined with urge, >8 mictions per day, and nocturia ≥2 voids/night, hence disrupted sleep. Patients who did not fulfil all the inclusion criteria were excluded. Further exclusion criteria were neurogenic hyperactive bladder, hypersensitivity to the study drug or its active compound or to drugs similar to the study drug, lactose intolerance, and the intake of bladder active drugs (anticholinergics, diuretics, bladder relaxing drugs including other phytomedicines) less than 4 weeks prior to study begin. Further exclusion criteria were acute UTI, pregnancy or lactation, drug or alcohol abuse, malcompliance, and participation in another study (current or during the last 4 weeks prior to inclusion in this study). Local systemic HRT was acceptable when started more than 4 weeks before study enrolment. A prior incontinence operation had to date back more than 6 months. Study information and informed consent were available only in German; hence, only German-speaking women were enrolled.
Mirzayeva N., Forst S., Passweg D., Geissbühler V., Simões-Wüst A.P, & Betschart C. (2023). Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial. Evidence-based Complementary and Alternative Medicine : eCAM, 2023, 2115335.
Full text: Click here
Publication 2023
Abuse, Alcohol Anticholinergic Agents Breast Feeding Diuretics Drug Allergy Lactose Intolerance Neurogenic Urinary Bladder Nocturia Patients Pharmaceutical Preparations Pregnancy Sleep Urinary Bladder Urination Woman
4
Clinical Impact of Bryophyllum pinnatum on Nocturia
By analogy to our previous observational studies in oncology and obstetrics on sleep quality and B. pinnatum, the study was designed to include a maximum of 50 patients [26 (link), 27 (link)]. At analysis, one patient had to be excluded due to a double entry in the database. Regarding nocturia, no observational study with B. pinnatum is available on which a power analysis could have been performed. Data were analysed using the IBM SPSS Statistics software for Windows, version 24. Overall, p values were calculated by the student's t-test for paired samples. A p value <0.05 was considered significant. Data are expressed as mean ± standard deviation (SD). The number of valid pairs is indicated if less than 49; missing values were not replaced.
Mirzayeva N., Forst S., Passweg D., Geissbühler V., Simões-Wüst A.P, & Betschart C. (2023). Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial. Evidence-based Complementary and Alternative Medicine : eCAM, 2023, 2115335.
Full text: Click here
Publication 2023
Neoplasms Nocturia Patients
5
Bryophyllum for Nocturia and Sleep Improvement
Patients filled out a 3-day voiding diary that includes fluid intake, frequency of voiding, urine volume in 24 hours (ml), urine volume at night (ml), urge intensity, urge episodes (+-+++), incontinence episodes (y/n), nocturia index (Ni), nocturnal polyuria index, and nocturnal bladder capacity index (NBCi).
The nocturia index (Ni) is calculated as nocturnal urine volume (NUV) divided by the maximal voiding volume for 24 hours; the nocturia index is defined as positive if it is greater than 1 Nocturnal polyuria is defined as NUV >33% of the total 24-h urine volume at the age of 65 years and higher. The NBCi corresponds to the actual number of voids minus the predicted number of voids. The predicted number of voids is obtained by subtracting 1 from the nocturia index (Ni) [34 (link)].
Four detailed questionnaires were filled out by the participants for all 7 days before the treatment with Bryophyllum 50% chewable tablets and during the last days of the 3-week-long treatment. For measuring the primary outcomes, nocturia and sleep quality, the averages of voiding at night from the 3-day voiding diary and the Pittsburgh Sleep Quality Index (PSQI, Questionnaire 1) were used. The PSQI is a self-report questionnaire that assesses sleep quality. It consists of 19 individual items that create 7 components that produce one global score (0–21) and takes 5–10 minutes to complete. These components (each one rated 0–3) are subjective sleep quality (component 1), sleep latency (component 2), sleep duration (component 3), habitual sleep efficiency (component 4), sleep disturbance (component 5), use of sleeping medication (component 6), and daytime dysfunction (component 7). The higher the score, the higher the symptom burden.
For the assessment of the secondary outcomes, the International Consultation on Incontinence Questionnaire-OverActive Bladder (ICIQ-OAB, Questionnaire 2) was used. This is a questionnaire for evaluating overactive bladder, its related impact on quality of life (QoL), and the outcomes of treatments in men and women in research and clinical practice. Higher values in the overall 0–16 score indicate increased symptom severity.
To assess daytime sleepiness as a sequela of night-time sleep disturbance, the Epworth Sleepiness Scale (ESS) (Questionnaire 3), which consists of 8 questions, was used. Adding the scores for each of the 8 questions yields a total score ranging from 0–24. An ESS score >10 suggests excessive daytime sleepiness (EDS); an ESS score ≥16 suggests a high level of EDS and is usually associated with marked sleep disorders, including narcolepsy.
Finally, the patients filled out a customized questionnaire (Questionnaire 4) on a daily basis to record discomforts and adverse events that they thought could be associated with the treatment and to characterize their tablet intake (forgotten tablets had to be registered); this allowed for the assessment of safety parameters and patient compliance.
Mirzayeva N., Forst S., Passweg D., Geissbühler V., Simões-Wüst A.P, & Betschart C. (2023). Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial. Evidence-based Complementary and Alternative Medicine : eCAM, 2023, 2115335.
Full text: Click here
Publication 2023
Bryophyllum Dyssomnias Excessive Daytime Sleepiness Narcolepsy Nocturia Overactive Bladder Patients Pharmaceutical Preparations Polyuria Safety Sleep Disorders Somnolence Urinary Bladder Urine Woman

Top products related to «Nocturia»

1
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
2
Jmp 14 by SAS Institute
Sourced in United States, Japan, Germany
JMP 14 is a data analysis software tool developed by SAS Institute. It provides statistical visualization and exploration capabilities for users to analyze and interpret data.
3
Sas software package version 9 by SAS Institute
Sourced in United States
SAS software package version 9.4 is a comprehensive data analytics platform that provides tools for data management, statistical analysis, and predictive modeling. It offers a range of functionalities, including data manipulation, advanced statistical techniques, and reporting capabilities. The software is designed to assist users in extracting insights from data and making informed decisions.
4
Spss statistics ver 24 by IBM
Sourced in United States, Japan
SPSS Statistics ver. 24.0 is a software application designed for advanced statistical analysis. It provides a comprehensive set of tools for data manipulation, analysis, and presentation. The software supports a wide range of statistical techniques, including regression, correlation, and hypothesis testing.
5
Spss statistics version 21 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, China
SPSS Statistics version 21 is a statistical software package developed by IBM. It is designed for data analysis and management, providing tools for data exploration, modeling, and reporting. The software offers a range of statistical techniques and is widely used in academic and professional research settings.
6
Chemiluminescence method by Siemens
Sourced in Germany
The Chemiluminescence method is a laboratory technique that measures the light produced by a chemical reaction. This method is used to detect and quantify various analytes, such as proteins, enzymes, and small molecules. The core function of this technique is to generate and measure the light emission that occurs during specific chemical reactions.
7
Stata 15 by StataCorp
Sourced in United States, United Kingdom, Austria, Denmark
Stata 15 is a comprehensive, integrated statistical software package that provides a wide range of tools for data analysis, management, and visualization. It is designed to facilitate efficient and effective statistical analysis, catering to the needs of researchers, analysts, and professionals across various fields.
8
Combur 9 test strips by Roche
Sourced in United States
The Combur 9 Test strips are a laboratory diagnostic tool used for the semi-quantitative or qualitative analysis of various parameters in urine samples. The test strips can detect the presence and approximate levels of analytes such as glucose, protein, pH, blood, and others. The Combur 9 Test is designed to provide healthcare professionals with a convenient and reliable method for basic urinalysis screening.
9
Spss statistics version 22 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Australia, Spain, Switzerland
SPSS Statistics version 22 is a statistical software application developed by IBM. It is designed to analyze and manipulate data, providing users with tools for data management, statistical analysis, and reporting. The software supports a wide range of data types and offers a variety of statistical procedures, enabling users to explore relationships, test hypotheses, and generate insights from their data.

More about "Nocturia"

Nocturia is a common condition characterized by the frequent need to wake up during the night to urinate.
This sleep disturbance can have various underlying causes, such as an overactive bladder, prostate issues, or hormonal imbalances.
Proper management of nocturia is crucial for ensuring restful sleep and overall well-being.
Researchers can leverage the power of PubCompare.ai to optimize their nocturia studies.
This innovative tool utilizes AI-driven comparisons to help researchers identify the best research protocols from literature, preprints, and patents.
By enhancing reproducibility and accuracy, PubCompare.ai can take your nocturia research to new heights and advance our understanding of this complex condition.
When studying nocturia, researchers may employ a variety of analytical techniques, such as the Chemiluminescence method or the use of Combur 9 Test strips.
Statistical software packages like SAS 9.4, JMP 14, SPSS Statistics (version 21, 22, or 24.0), and Stata 15 can be utilized to analyze the data and derive meaningful insights.
By incorporating these tools and techniques, researchers can delve deeper into the nuances of nocturia, unraveling the underlying mechanisms and developing more effective treatment strategies.
With the help of PubCompare.ai, researchers can streamline their nocturia studies, ensuring reproducibility and accuracy, and ultimately contributing to the advancement of our knowledge in this important area of healthcare.